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Background: Invasive (IPD, defined as detection of pneumococci in sterile body fluids like meningitis or bacteremic
pneumonia) and non-invasive Streptococcus pneumoniae infections (i.e. non-bacteremic pneumonia, otitis media) in
adults are associated with substantial morbidity, mortality and costs. In Germany, Pneumococcal polysaccharide
vaccination (PPV23) is recommended for all persons >60 years and for defined risk groups (age 5–59). The aim of
this model was to estimate the potential cost-effectiveness and benefit-cost ratios of the adult vaccination program
(18 years and older), considering the launch of the pneumococcal conjugate vaccine for adults (PCV13).
Methods: A cross-sectional steady state Markov model was developed to estimate the outcomes of PCV13, PPV23
vaccination schemes and ‘no vaccination’. Conservative assumptions were made if no data were available for PCV13
and PPV23 respectively. The effectiveness of individual pneumococcal vaccination in adults was adjusted for
expected indirect effects due to the vaccination in infants. Data on incidences, effectiveness and costs were derived
from scientific literature and publicly available databases. All resources used are indicated. Benefit-cost ratios and
cost-effectiveness were evaluated from the perspective of the German Statutory Health Insurance as well as from
social perspective.
Results: Under the assumption that PCV13 has a comparable effectiveness to PCV7, a vaccination program with
PCV13 revealed the potential to avoid a greater number of yearly cases and deaths in IPD and pneumonia in
Germany compared to PPV23. For PCV13, the costs were shown to be overcompensated by monetary savings
resulting from reduction in the use of health care services. These results would render the switch from PPV23 to
PCV13 as a dominant strategy compared to PPV23 and ‘no vaccination’. Given the correctness of the underlying
assumptions every Euro spent on the PCV13 vaccination scheme yields savings of 2.09 € (social perspective: 2.16 €)
compared to PPV23 and 1.27 € (social perspective: 1.32 €) compared to ‘no vaccination’, respectively.
Conclusions: Results of the model indicate that the health economic benefit of immunizing adults with PCV13 can
be expected to outperform the sole use of PPV23, if the effectiveness of PCV13 is comparable to the effectiveness
of PCV7.
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Streptococcus pneumoniae (pneumococcus) is worldwide
a leading cause of infections associated with high case
fatality rates like sepsis, meningitis and pneumonia. Of
the 91 identified pneumococcal serotypes, 10 to 15 pose
major risks to morbidity and mortality, particularly in
young children (age ≤5 years (y)), elderly (age ≥65 y) and
immunocompromised patients (all age groups). In addition,
pneumococcus is the most common cause of community-
acquired pneumonia (CAP) in adults.
In 2001, a 7-valent pneumococcal conjugate vaccine
(PCV7) became available in Europe for children. Higher-
valent PCVs were launched in 2009, a 10-valent (PCV-10)
and a 13-valent pneumococcal conjugate vaccine (PCV13).
Since August 2006 the Standing Vaccination Committee at
the German Robert-Koch Institute (STIKO) recommends
vaccination of all children less than two years of age. In
addition, children at risk should be vaccinated between the
ages of 3 and 5 years, since August 2010 with the 13-valent
pneumococcal conjugate vaccine. The conjugate vaccine
induces a strong antibody response in children and reduced
significantly the incidence of IPD in Germany [1] and other
European countries.
Contrary to the recommendations for children, the 23-
valent pneumococcal polysaccharide vaccine (PPV23) is
still the recommended vaccine in Germany for preven-
tion of pneumococcal diseases in elderly (age ≥60 y) and
adults at risk despite the ongoing controversy regarding
its effectiveness. A recently published meta-analysis and
a series of published studies did not confirm the effect-
iveness of PPV23 and concluded that policy-makers
should reconsider their current recommendations for the
use of the pneumococcal polysaccharide vaccine, espe-
cially when pneumococcal conjugate vaccine get licensed
for adults [2-12].
The T-cell dependent immune response of PCV13
induces antibody titres in elderly comparable to those
induced in infants. [13] Vaccination studies have shown
that antibody levels after PCV13 were at least similar or
superior for most vaccine shared serotypes to that
induced by PPV23. However, implementing a PCV13
vaccination scheme in adults will cause additional costs
in the German health care system due to the higher
price of the vaccine. Therefore, this analysis aims to
evaluate the benefit-cost ratio and cost-effectiveness of
an adult vaccination program in individuals older than
50 years compared to the existing PPV23 recommenda-
tion for adults as well as to ‘no vaccination’.
Methods
Model structure
To compare the benefit-cost ratio and cost-effectiveness
of three different pneumococcal vaccination strategies
(PPV23, PCV13 and ‘no vaccination’) in adults, weupdated and extended a recently developed Markov
model. The analysis focused on a comparison between a
PCV13 and a PPV23 vaccination strategy. Therefore, we
simulated a setting in which both vaccination programs
were fully established according to the vaccination
recommendations in Germany. For the following, we de-
fine this setting, in which all new entrants of the target
groups were being vaccinated or re-vaccinated and all
other individuals were already immunized according to
the vaccination recommendations and assumed vaccin-
ation rates, as a steady state. Hence, time series of start-
ing and establishing a vaccination were not included in
the analysis. The evaluation took the perspective of the
German Statutory Health Insurance (SHI), and addition-
ally estimated social work loss costs. Outcomes and
costs of each vaccination strategy for one year in a
steady state were calculated in two steps.
Due to a lack of epidemiological data, we estimated
the population at risk (distinguishing between normal,
moderate and high risk of pneumococcal disease) in 83
age groups (18–100 years of age) in the above men-
tioned setting as well as the proportion of immunized
individuals due to vaccination in each age/risk group
using a Markov state transition model with a time hori-
zon of 100 years. The cycle length was one year. In par-
ticular, the model took account for effects of immunized
individuals transiting to other risk groups over time. The
population simulation started with healthy and unvac-
cinated newborns developing age-specific risk of comor-
bidities with increasing age which are associated with
moderate or high risk of pneumococcal disease. Each
risk group got vaccinated according to the strategies
described below. Group members at moderate or high
risk remained in their risk group during the simulation.
Transition to death was possible from all states. In order
to account for the age distribution of the German popu-
lation, each age group was weighted according to the
German population structure in the year 2008 [14].
Secondly, for the modelling of cost-effectiveness num-
ber of cases and deaths per year due to pneumococcal
diseases were estimated for each vaccination strategy
based on the results of the simulated population. To
avoid interferences with the recently published children
model, children and adolescents were excluded. Risk and
age specific morbidity and mortality rates as well as the
effectiveness of the vaccination were taken into account.
In addition, the risk model calculated the yearly costs of
the vaccination programs and yearly treatment costs for
pneumococcal diseases.
The time horizon of one year avoided discounting, a
topic of high relevance and unclear positioning in the in-
dication of prevention. On the other hand, the cross sec-
tional design of the model neglected costs associated
with the implementation of a new vaccine combined
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might be of interest regarding the budget impact of a
new vaccination program.
The model was constructed in Microsoft Excel 2007.
Vaccination strategies/choice of comparators
In Germany PPV23 vaccination is generally recom-
mended for adults ≥60 y and for all patients >5 y with
comorbidities and increased risk of pneumococcal dis-
ease. Since 2009, revaccination every 5 years is restricted
to patients with immuno-compromising conditions due
to frequent adverse events at the site of injection and
questionable effectiveness of the vaccine [15].
To estimate the effects of PCV13 vaccination, a hypo-
thetical vaccination program with vaccinating adults older
than 50 years (branch 1=PCV13) was compared to the
existing PPV23 recommendation (branch 2=PPV23). In
the PCV13 branch, we assumed that adults at risk were
vaccinated with PPV23 until they reached the age of 50.
Thereafter they switched to PCV13 when they were revac-
cinated. That goes in line with current recommendation
for pneumococcal vaccination and the targeted label for
PCV13. Adults developing comorbidities associated with
moderate or high risk of pneumococcal disease after the
age of 50 were initially and revaccinated with PCV13 as
were seniors with normal risk who got their initial vaccin-
ation at the age of 60, analogous to the PPV23 recommen-
dation. For PCV13 the need for a revaccination in adults
has not been established. Nevertheless we assumed a de-
cennial booster, based on the experience of pneumococcal
conjugate vaccination in children [16-18].Figure 1 Simplified structure of the model.Due to the lack of data, we had to assume vaccination
rates for initial and booster vaccination. Considering
that the population at risk gets a higher awareness, ini-
tial vaccination rates were assumed to be higher than in
the risk free population (40% vs. 25%). PPV23 booster
vaccination was only considered for every patient in the
high risk groups according to STIKO recommendations
[15,19]. In contrast, PCV13 booster vaccination was consid-
ered for every patient at risk and every second without any
risk. Due to the assumed superior effectiveness of PCV13
restrictions regarding revaccination are not expected.
In a third branch we modelled the ‘no vaccination’ sce-
nario representing the strategy not to prevent but to
treat pneumococcal disease. We included this scenario
to analyse the total effects of both vaccines in addition
to the incremental effects of PCV13 versus PPV23.
Epidemiology
The simulated model population (see Figure 1, popula-
tion simulation model) size was around 82,000,000 indi-
viduals representing the estimated German population
of adults in 2008. [14] The age structure of the initial co-
hort and the number of patients at risk, estimated
according to data of Fleming et al., are shown in Table 1.
Calculation of life expectancy was based on the German
life tables from 2007/2009 [20], while the population
structure was taken from the German Federal Statistical
Office (2008) [14]. In 2008, the overall German popula-
tion of 82.0 million continued to decrease. Following the
trend of recent years the age group >60 y continues to
grow. To model the cost-effectiveness, a population size
Table 1 Simulated population size (total population)
Age group General population High risk* Moderate risk*
< 5 2,730,000 4,600 16,000
5 - 17 10,070,000 75,100 260,000
18 - 39 21,700,000 405,000 1,400,000
40 - 59 25,500,000 1,001,000 2,777,000
60+ 22,000,000 2,874,000 7,415,000
Total 82,000,000 4,359,700 11,868,000
*Estimated according to Fleming et al. [21].
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different risk groups.
In contrast to the health economic endpoint, the epi-
demiological endpoints are avoidable episodes of IPD
and non-bacteremic CAP in an inpatient setting as well
as in an outpatient setting. Historical incidences for IPD
in adults are taken from a regional surveillance study in
North-Rhine Westphalia prior to the general PCV vac-
cination recommendation for children. The age-specific
IPD incidence was adjusted for underreporting with a
factor of 2.7, due to the very low standard with regard to
the collection of blood cultures in Germany.
The burden of pneumococcal pneumonia is high and
the most serious complication is a bacteremic course
associated with a high case fatality rate. The CAP inci-
dence incorporated all causes as detailed microbiological
diagnosis is not performed on a regular basis. Data on in-
cidence of CAP treated in hospital (“inpatient CAP”) are
based on the German hospital admission data (2008).
[22] The BQS-Report documented that 200,000 CAP epi-
sodes were treated within hospital every year, which is
very close to the numbers incorporated in our model
based on admission data. [23] Age specific incidence of
CAP treated in primary care settings (“outpatient CAP”)
were derived from a representative pharmaceutical pre-
scription panel which results (12 episodes in 1,000
adults) were similar to results reported in the literature.
[24] For Schleswig-Holstein (a Northern region inTable 2 Incidence (per 100,000 individuals) and Case Fatality
Age group IPD
Incidence CFR Incidence
18 - 39 0.5 14.9% #
40 - 49 6.8 14.9% #
50 - 59 13.3 14.9% #
60 - 69 23.0 14.9% #
70 - 79 41.6 16.5%
80+ 53.7 27.4% 1
} including a factor of 2.7 for underreporting (29), # assumption,
CAP: community acquired pneumonia, CFR: case fatality rate, IPD: Invasive PneumoGermany), incidence of CAP ranged between 3.7 and
12.3 cases per 1,000 adults.
Due to the lack of valid data, odds ratios for IPD and
CAP incidences in moderate and high risk population
were assumed to be 1.5.
The IPD case fatality rate (CFR) for adults was taken
from the literature (US 2000–2004). In comparison, the
German CFR due to streptococcal and other sepsis cases
(ICD A40, A41, A49.1 and G00.1) in the age groups <15,
15 - < 45, 45 - < 65, 65 - < 75, 75 - < 85 and ≥85 was 1.20%,
3.56%, 7.23%, 9.63%, 14.93%, 21.24%. [22] The study of
Dzupova et al. confirmed a CFR for adult pneumococcal
meningitis of 20%.
The 6 months CFR of inpatient CAP was based on data
from the German CAPNetz [25]. While the CFR in CAP
in outpatient settings amounted to about 1%, CFR in in-
patient CAP was higher (see Table 2). CFR for outpatient
CAP was assumed to be 0% for patients <60 y and 0.5%
for patients being 60y and older.
Effectiveness
The effectiveness of different pneumococcal vaccines
depends on immunization level, vaccine efficacy in inva-
sive and non-invasive pneumococcal diseases differen-
tiated to age and risk groups, serotype coverage, vaccine
effectiveness against cross-reactive serotype, and dur-
ation of protection, replacement, revaccination, indirect
(herd) effects in the same target group, and indirect
(herd) effects from vaccination of children. Data for vac-
cine efficacy and effectiveness are shown in Table 3.
According to published data and adaption of general
recommendation, we calculated IPD effectiveness of both
vaccines using efficacy data, adjusted to serotype distribu-
tion in Germany for all age groups.
For PPV23, IPD data were derived from a Cochrane
meta-analysis [9] reporting an correlate IPD efficacy of
74% (with no present statistical heterogeneity when all
RCT´s were considered). However, the reported correl-
ate IPD efficacy was not representative for subgroups
e.g. population with chronic illness in high incomeRate (CFR)
Inpatient CAP Outpatient CAP
[22] CFR [25] Incidence [24] CFR#
48.9 1.6% 574.7 0.0%
80.4 4.3% 777.3 0.0%
149.7 6.3% 1,074.0 0.5%
350.4 10.8% 1,459.3 0.5%
768.7 16.8% 1,465.8 0.5%
,897.8 22.6% 2,025.2 0.5%
coccal Disease.
Table 4 Factor for correction of indirect (herd) effects
Age group IPD CAP
15 - 39 37,4%* 23.6%*
40 - 44 39.7%* 23.6%*
45 - 49 39.7%* 16,2%*
50 - 64 17.5%* 16,2%*
65+ 37.9%* 14.3%*
*Adjusted according to Claes et al. for German serotype coverage based on
IPD data from Pilishvili et al. and CAP data from Ray et al. [34].












40 - 49 75.4% 78.5%
50 - 59 63.4% 78.9%
60 - 69 63.9% 83.6%
70 - 79 71.4% 78.3%
80 - 89 74.8% 84.5%
≥ 90 76.2% 90.5%
Inpatient CAP / Outpatient CAP (all cause)
Age Group Effectiveness Effectiveness
All 26.0%/6% [27,28] 0%/0% [6,9,19]
* =multiplication.
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56% to 85%. So we used the upper and lower bound for
sensitivity analysis. In contrast, the reported efficacy data
for CAP were inconclusive with substantial statistical het-
erogeneity [9]. Incorporating the findings from a Canadian
meta-analysis [6] the conclusion can be drawn, that
PPV23 does not appear to be effective in preventing CAP.
Therefore, we assumed in the base case analysis that
PPV23 is ineffective in preventing CAP. We abandoned
this assumption in the sensitivity analysis by calculating
the economical outcomes of PPV23 effectiveness against
inpatient CAP according to Maruyama et al. [29].
For PCV13, assumption on IPD efficacy was based on
clinical data for PCV7 in children for all patients, expect-
ing similar levels of efficacy against the additional 6 sero-
types which are not included in PCV7. Serotype coverage
was calculated on the basis of data reported by Reinert
et al. [30] Effectiveness of initial vaccination on inpatient
and outpatient CAP for PCV13 was assumed to be 26%
and 6%, respectively, according to effectiveness data on
PCV7 [27,28].
We assumed that vaccines were equally effective
against all vaccine serotypes, and further assumed that
effectiveness of revaccination with PCV13 and PPV23
was the same as that of initial vaccination. Immunization
due to vaccination with PCV13 and PPV23 was assumed
to be effective for 10 years and 5 years, respectively.
Then the effects wane completely.
In our model, we assumed that childhood vaccination
programs with PCV7 were already established. Since
children vaccinated with a conjugated vaccine are un-
likely to be carriers for the seven vaccine serotypes, they
can no longer transmit these to others. In particular, eld-
erly benefit from this indirect protection. Vaccinatedchildren, vaccinated successfully, are no carrier of patho-
gens. Indirect effects reduced probability of infection in
the elderly. Evidence for indirect effects was reported
from the US and Australia [31-36].
Markov cohort models are not able to directly capture
indirect herd effects based on transmission dynamics of
infectious disease. Hence, we included one additional par-
ameter “herd effects” in our model. To address indirect
effects from the childhood vaccination, the effectiveness
of adult vaccination was reduced by a factor of “herd
effects”. The disease and age group specific values for this
correction factor are shown in Table 4. The figures were
calculated based on US data from Ray et al. [34] and
Pilishvili et al. [37] adjusted for German serotype coverage
according to Claes et al. [38]. Effects due to serotype re-
placement were not included. In contrast to the childhood
PCV vaccination, adults receive just one dose of vaccine
which is expected to be insufficient to induce any herd
effects. In addition, PPV23 is unable to elicit immune
memory, so that also a second dose of vaccine would not
boost antibody level and therefore would not cause signifi-
cant herd effects [39]. Hence, herd effects due to adult
vaccination were not included in the model.
Economic parameters
Life years gained (LYG) were the primary health-
economic endpoint in our analysis. Prices and utilization
of health services per unit were modeled separately. We
evaluated the resource use from the perspective of the
SHI in Germany, taking into consideration patient co-
payments as well as discounts for medications given by
the manufacturer and pharmacies as required by legal
obligations in Germany. In addition, we estimated costs
from a social perspective, including costs for work loss
and patients co-payments. To evaluate the costs from
the perspective of the SHI, the current German guide-
lines for the valuation of resource usage were applied.
Costs referred to the year 2010.
Costs of medical care of pneumococcal associated
infections
In the German health care system, inpatient treatment is
reimbursed by G-DRG and outpatient treatment by
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Table 5 summarizes the costs, which were integrated
into the model. We assumed that all IPD cases were
treated in hospitals due to the severity of invasive infec-
tion. Further we assumed that 20% of all inpatient CAP
cases took a more severe course. No cost for long-term
disabilities from IPD and CAP were included.
Inpatient costs were derived from official G-DRGs
codes (German Diagnosis Related Groups) in 2010
which are calculated based on resource use in 2008 (see
Table 5). [40] These costs are lump sums and cover all
cost per case which includes, in general, all expenses of
the hospital (incl. medication costs). The G-DRG system
separately covers the specific need for mechanical venti-
lation. According to this we assumed 13% [41] and 11%
[42] cases with mechanical ventilation for IPD and mod-
erate inpatient CAP respectively. For severe inpatient
CAP the DRG code E77A covers cases with a high de-
gree on co-morbidities and complex intensive care
treatment.
Regarding the outpatient setting, we applied the offi-
cial German Uniform Valuation Scheme (EBM). [43] For
general outpatient physician visits of SHI-insured per-
sons the doctors are reimbursed via capitation fees per
quarter, independent from the number of visits of a pa-
tient per quarter. The costs of outpatient care consisted
of a quarterly capitation fee in 2010: 6y–59y 30.84 €






PCV13 including administration All 71.57 €
(71.57 €
PPV23 including administration All 35.89 €
(35.89 €
IPD All 9,006.43 €
(9,151.90 €
IPD letal All 1,445.41 €
(1,445.41 €
Inpatient CAP, severe All 8253,93 €
(8371,93 €
Inpatient CAP, moderate All 5119,33 €
(5185,99 €
Outpatient CAP 5-59 54,75 €
(54,75 €
Outpatient CAP 60+ 59,65 €
(59,65 €
Non-medical c
Cost for work disability per day All 95.72 €1020*0.035048) plus an average compensation for pre-
scriptions of 23.91 € per episode generated from the
IMS prescription panel [24,43]. The average compensa-
tion was calculated on the basis of prescription costs
and prescription quantity of ICD10 diagnosis (J12–J18).
No extra costs for treating adverse events from vaccin-
ation were considered in the model.
Costs of the vaccination program
Based on official data and a package size of ten [44] the
pharmacy retail price of PCV13 was determined to be
64.62 € per dose PCV13 and 28.94 € per dose for
PPV23. There is no official rule for vaccine pricing in
Germany. Therefore no manufacturer and pharmacy dis-
counts were subtracted from the pharmacy retail prices
for vaccines. Based on a sample of German vaccination
agreements between the Association of SHI Physicians
and the SHI we calculated an average reimbursement fee
of 6.95 € for each injection. It was assumed that the vac-
cine is administered at the same time as other vaccines
so no further visit costs are incurred.
Indirect costs
Regarding the social perspective cost of work loss and
patient’s co-payments were included in the analysis. The
cost of work loss was calculated using the human capital
approach as proposed by the “Hannoveraner Konsens” [45].




Lauer-Taxe (2010), German vaccination agreements
of the SHI
)
Lauer-Taxe (2010), German vaccination agreements
of the SHI
)
G-DRG (2010) 87% mean
G-DRG T60A-C+ T60E + 13% weighted mean






G-DRG (2010) 89% weighted mean G-DRG E77A-D+
11% weighted mean G-DRG A06A-B, A07A-E, A09A-F,
A11A-G, A13A-G
)
EBM-Code (2010) 03110, IMS Health Deutschland
)
EBM-Code (2010) 03111, IMS Health Deutschland
ost
Federal Statistical Office 2010
Table 6 Cases, avoidable episodes and deaths
IPD Inpatient CAP Outpatient CAP total
Cases without vaccination
Episodes 16,145 207,007 693,645 916,797
Deaths 2,730 34,385 1,949 39,064
Cases with PPV23
Episodes 15,581 207,007 693,645 916,233
Deaths 2,633 34,385 1,949 38,967
Cases with PCV13
Episodes 14,784 194,900 688,104 897,788
Deaths 2,478 32,003 1,922 36,403
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; 81.8% for men and ; 69.6% for women, daily cost for
work disability of 95.72 € were considered as indirect
cost in the model [46,47].Sensitivity analysis
To access the impact of various parameters on model
outcomes and to confirm the robustness of the model,
all parameter values were varied individually in one-way
sensitivity analysis (SA) and simultaneously in a prob-
abilistic SA with 10.000 iterations. For probabilistic SA,
beta distributions were assumed based on published 95%
confidence intervals. If confidence intervals or ranges were
not reported in the studies, we assumed an upper and
lower limit of ±25% of the base case value. To account for
skewness in cost data we used gamma distributions.
Means and standard errors were derived from the corre-
sponding databases (DRG Browser [40], IMS prescription
panel [24]). Means, standard errors, and distributions for
all parameters examined in the probabilistic sensitivity
analysis are shown in the Appendix.Results
Estimated effects on IPD and CAP according to the dif-
ferent vaccination strategies are shown in Table 6. Main-
taining vaccination with PPV23, 916,233 episodes andTable 7 Cost-effectiveness and benefit-cost ratio
PCV13 vs. PPV23
Cost-effectiveness
Additional vaccination cost (€) 36,322,624
Cost savings (€) 75,907,677
Life years gained 22,942
ICER (cost per life year gained) −1,725
Benefit-cost ratio
Direct cost 2.09
Direct cost + indirect cost 2.1638,967 deaths related to pneumococcus-induced diseases
could be expected each year, which is a reduction of 564
episodes and 97 deaths in comparison to ‘no vaccination’
against pneumococcal diseases. Assuming the PCV7 ef-
fectiveness data, with PCV13 vaccination (vaccination in
adults older than 50 years) 19,009 episodes and 2,661
deaths could be avoided in comparison to ‘no vaccination’.
The results of the base case analysis (Table 7) indi-
cated that switching to PCV13 in adults older than
50 years was cost-effective compared to PPV23 as well
as to ‘no vaccination’ and dominated both strategies.
According to our model, 22,942 additional life years can
be gained by offering PCV13 instead of PPV23 and
24,480 life years can be saved by the PCV13 vaccination
program compared to the ‘no vaccination’ scenario. The
estimated benefit-cost ratio of PCV13 was 2.09 (2.16 in-
cluding indirect costs) compared to PPV23 and 1.27
(1.32 including indirect costs) compared to ‘no vaccin-
ation’, respectively. Hence, additional cost savings via
avoided health care services overcompensated costs
related to PCV13 vaccination in adults aged >50 y. The
main driver is the prevention of inpatient CAP cases
accounting for 80 to 90% of the overall monetary savings
of PCV13 over PPV23 and ‘no vaccination’, respectively.
Figure 2 shows results of the one way SA when the
same variation factor (+/−25%) was assumed. Overall,
the higher the PCV13 price as well as the indirect herd
effects, the lower the benefit-cost ratios. Otherwise the
higher the incidence rates, the PCV13 effectiveness as
well as the medical costs the higher the benefit-cost
ratio. Results of one way SA were highly sensitive to var-
iations of the PCV13 price as well as all parameters of
inpatient CAP and less sensitive to variations of vaccin-
ation rates, indirect herd effects as well as all parameters
related to IPD. Variations of parameters related to out-
patient CAP had no impact. Lower PCV13 vaccination
rates in the normal risk group increased the benefit-cost
ratio.
In addition, we tested extreme scenarios, e. g. revac-
cination frequency of PCV13 = 5 years, no indirect herd-







Figure 2 Results of one way sensitivity analyses.
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Even if the monetary net benefit of the PCV13 strategy
compared to PPV23 vaccination was negative in some of
these scenarios, PCV13 vaccination would be a cost-
effective option according to a ICER threshold (assumed
between 20,000 and 50,000 €/LYG). Regarding the
Maruyama et al. [29] scenario (PPV23 inpatient CAP ef-
ficacy = 45%) the PCV13 vaccination program would still
be cost-effective with an ICER of 590 €/LYG compared




PCV13 revaccination according to current PPV23
adult vaccination recommendations in Germany [15]
2.97
Revaccination PCV13 not needed 16.74
Revaccination PCV13 every 5 years 0.97
Incidence for in- and outpatient CAP according to
Schnoor et al.: -55% [48]
1.01
PPV23 effectiveness against IPD upper limit [9] 2.07
PPV23 effectiveness against IPD lower limit [9] 2.12
PPV23 effective in preventing inpatient CAP according
to Maruyama et al. [29]: 45%
0.86
PCV13 ineffective in preventing in- and outpatient CAP 0.17
No indirect herd effects of PCV7 vaccination 2.51In a case that PCV13 is completely ineffective in pre-
venting CAP, the ICER of PCV13 compared to PPV23
was 17,983 €/LYG and compared to ‘no vaccination’
16,440 €/LYG.
Figure 3 and 4 illustrate the results of the probabilistic
sensitivity analysis. The minimum benefit-cost ratios of
PCV13 in comparison to PPV23 as well as ‘no vaccin-
ation’ were 0.62 (0.65 including indirect cost) and 0.41
(0.44 including indirect cost), respectively. PCV13 domi-
nated PPV23 with a probability of 99.51% and ‘noBenefit-cost ratio
PCV13 vs. ‘PPV23
Benefit-cost ratio








€ 2.16 € 1.27 € 1.32 €
€ 3.11 € 1.08 € 1.14 €
€ 17.26 € 2.81 € 2.92 €
€ 1.00 € 0.75 € 0.78 €
€ 1.05 € 0.65 € 0.68 €
€ 2.14 € 1.27 € 1.32 €
€ 2.19 € 1.27 € 1.32 €
€ 0.88 € 1.28 € 1.34 €
€ 0.17 € 0.16 € 0.18 €
€ 2.60 € 1.54 € 1.61 €
Figure 3 Probabilistic sensitivity analysis boxplots.
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the simulation.
Discussion
This study is the first to describe the benefit-cost ratio
and cost-effectiveness of a PCV13 vaccination scheme
for adults in Germany. The model found that switching
from PPV23 to PCV13 in adults older than 50 years was
a dominant strategy. Compared to PPV23 as well as ‘no
vaccination’, the PCV13 vaccination program revealed
the potential to avoid a greater number of yearly cases
and deaths due to the potential superior efficacy of
PCV13 in IPD and CAP in Germany. One way sensitiv-
ity analyses illustrated PCV13 attained a positive net
benefit over PPV23 and over ‘no vaccination’ in most of
the tested scenarios and an acceptable ICER in all tested
scenarios. Variations in input parameters related to in-
patient CAP as well as the price of PCV13 had the most
significant impact on the results.
The study was mainly limited by lacking clinical data
on conjugate vaccine in adults. Except for a study in
HIV-infected adults in Malawia using PCV7, no data are
available for an effect of conjugate vaccine in adults.
Therefore, data on the vaccine efficacy and effectiveness
in infants were used as basis for the assumptions and
the fact, that immunogenicity data in adults were com-
parable to immunogenicity data in children. Initial stud-
ies for antibody detection underline these assumptions
for PCV7 and PCV13 respectively.
There was a lack of evidence for the duration of pro-
tection of PPV23 [9]. Different values were publishedregarding the PPV23 serotype effectiveness against IPD.
Therefore, we decided for the base case scenario to use
the recommendations according to the Cochrane meta-
analysis [9].
In terms of pneumonia four randomized, placebo-
controlled trials of vaccination with PPV23 in COPD
(chronic obstructive pulmonary disease) have failed to
show a significant reduction in mortality, hospitalization,
or pneumonia. However, a recent randomized placebo
controlled trial in Japanese nursing home residents
(85 +/− 8y) revealed a reduction of all cause pneumonia
by 45% and of pneumococcal pneumonia by 64%. The
reason for these discrepancies remains unclear.
Since data regarding the waning efficacy of PCV13
vaccine are not available, several publications for PPV23,
which value the issue of waning, were considered. For
PPV, antibody levels to several serotypes decline to pre-
vaccination values within 5–10 years corresponding to a
decline of protection. Existing immunogenicity data sug-
gest that PCV will provide a long-lasting immunologic
memory and protection. [49,50] This issue will be
addressed in upcoming publications.
Although evidence of indirect (herd) protection for
vaccination in children is demonstrated for North Rhine
Westphalia, Saxony and Bavaria we decided to use data
from U.S, were evidence is confirmed for the whole
population. [51] A study by Ardanuy et al. showed evi-
dence of a decrease in IPD due to PCV7 serotypes for
hospitalised adults in Spain for adults aged 18–64
(results not significant) and adults over 65 (significant
results). [52] As mentioned in section two, we modelled
Figure 4 Probabilistic sensitivity analysis scatterplots.
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double counting indirect (herd) effects from children
vaccination were excluded. Therefore results in terms of
case reduction may be underestimated.
Our results were based on the premise that no re-
placement of serotypes (i.e., an increase in carriage of
and disease from serotypes not included in the vaccine)
will take place in Germany, though other studies have
noted the importance of collecting data on the impact of
serotype evolvement on future evaluations of vaccines
for pneumococcal disease. This assumption is obviously
in contrast to numerous studies showing serotype shift-
ing after introduction if the vaccine and first signs of sero-
type shifting have already been observed in Germany. [53]
However, since the most of the replacement serotypes,particularly the main replacement serotype 19A, is con-
tained in the novel PCV13, a substantial replacement to
this vaccine cannot be foreseen. Some authors also assume
that replacement serotypes are less fit and virulent com-
pared to the predominant vaccine serotypes before intro-
duction of PCV 7.
In our base case analysis the ICER of PPV23 compared
to ‘no vaccination’ was 14,751 €/LYG, which was com-
parable to results of a published health economic review.
[54] This review showed that PPV23 vaccination was a
cost-effective option in vaccination over 65 years old
mainly in prevention of IPD in most of the studies.
Compared to PCV13, vaccination with PPV23 was an in-
ferior strategy in our model. That goes in line with a re-
cently published study, evaluated the economic impact
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in the US. [55] A published model from the Netherlands
estimated the cost-effectiveness of PCV13 compared to
‘no vaccination’ in adults’ aged ≥65 y. The results of the
base case analysis indicated that PCV13 was cost-
effective but not dominant. However, the model of
Rozenbaum et al. had only a time horizon of five years. [56]
We simulated a similar scenario in our model by reducing
the revaccination frequency of PCV13 from 10 to 5 years.
PCV13 would lose its dominance but still remained cost-
effective compared to PPV23 as well as ‘no vaccination’.
Most of the previous mentioned health economic stud-
ies used the target population, vaccinated routinely in
many countries. Effectiveness of PPV23 is discussed
controversially. There is a homogeneous consensus that
PPV23 has no protection against non-bacteremic pneu-
monia [9]. Only protection against IPD is assessed differ-
ently. Therefore we decided to us no decline in protection
for both vaccines even if most of the PPV23 studies con-
sidered a decline in protection with different rates.
The focus of this study was to address the benefit of
pneumococcal conjugate vaccination in adults. Adverse
events are not a problem with conjugate vaccines. For
PPV23 only a small impact of adverse events on ICER
was shown. Therefore we decided not to implement cost
for adverse events in the current model.
Considering the substantial morbidity, mortality and
costs associated with pneumococcal disease as well as
the limitations of Markov models to simulate the dy-
namics of transmissible disease, there is a need for more
accurate models as soon as valid effectiveness data of
PCV13 is published to confirm the cost-effectiveness of
this vaccine.
Conclusions
In conclusion, our analysis indicates that adult PCV13
vaccination in Germany will reduce the burden of
pneumococcal disease with substantial health and eco-
nomic benefits when compared to the currently recom-
mended PPV23 as well as ‘no vaccination’. However,
final cost-effectiveness will depend mainly on efficacy
data of PCV13 confirmed by clinical trials, particularly
in inpatient CAP. Defining the risk population, vaccin-
ation rates, indirect (herd) effects and serotype replace-
ment needs further research.
Appendix A
Sensitivity analysis
The tables below provide information on the parameters
included in the probabilistic sensitivity analysis as well
as additional results of the one-way and multi-way sensi-
tivity analyses. The means, standard errors and the type
of distributions of all parameters examined in the prob-
abilistic analysis are shown in Additional file 1: Table S1.Additional file 2: Table S2 illustrates the results of all
one-way and multi-way sensitivity analyses conducted.Additional files
Additional file 1: Table S1. Means, standard errors and distributions of
parameters examined in the probabilistic sensitivity analysis.
Additional file 2: Table S2. One-way and multi-way sensitivity analyses.
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